Compositions and methods for modulation of immune response

Abstract

Provided herein are compositions and methods for modulation of immune response via PYRIN domain-only proteins POP1 and/or POP3. In particular, POP1 and/or POP3 are inhibited to enhance an immune response (e.g., to treat or prevent infection), or POP1 and/or POP3 are administered or activated to reduce an immune response (e.g., to treat or prevent autoimmune or inflammatory disease).

1 . A method of treating or preventing a disease or condition associated with inflammation comprising administering a composition that increases the activity of POP1, POP2, and/or POP3. 
     
     
         2 . The method of  claim 1 , wherein the composition comprises a POP1, POP2, and/or POP3 polypeptide, peptide, or peptidomimitic. 
     
     
         3 . The method of  claim 2 , wherein the polypeptide or peptide comprises 100% sequence identity with all or a portion of POP1, POP2, or POP3. 
     
     
         4 . The method of  claim 2 , wherein the polypeptide or peptide comprises less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3. 
     
     
         5 . The method of  claim 1 , wherein the composition comprises an agent that enhances the inflammasome inhibitory activity of POP1, POP2, and/or POP3. 
     
     
         6 . The method of  claim 5 , wherein the composition is a small molecule, peptide, polypeptide, protein, or antibody. 
     
     
         7 . The method of  claim 1 , wherein the disease or condition is an autoimmune disease. 
     
     
         8 . The method of  claim 1 , wherein the disease or condition is an inflammatory disease. 
     
     
         9 . The method of  claim 1 , wherein the composition is co-administered with one or more additional treatments for the disease or condition 
     
     
         10 . A method of treating or preventing infection comprising administering a composition that inhibits the activity of POP1, POP2, and/or POP3. 
     
     
         11 . The method of  claim 10 , wherein the composition is a small molecule, peptide, polypeptide, protein, or antibody. 
     
     
         12 . The POP1, POP2, or POP3 protein, polypeptide, or peptide that comprises less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3. 
     
     
         13 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use as a medicament. 
     
     
         14 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of  claim 13 , comprising less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1 or POP3. 
     
     
         15 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of  claim 13  for use in the treatment or prevention of an autoimmune or inflammatory disease or condition. 
     
     
         16 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use in the treatment or prevention of an autoimmune or inflammatory disease or condition. 
     
     
         17 . A POP1, POP2, or POP3 inhibitor. 
     
     
         13 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use as a medicament. 
     
     
         14 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of  claim 13 , comprising less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3. 
     
     
         15 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of  claim 13  for use in the treatment or prevention of an autoimmune or inflammatory disease or condition. 
     
     
         16 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use in the treatment or prevention of an autoimmune or inflammatory disease or condition.